Stock listing
ARVN Stock Price, News, Filings & Events — Arvinas, Inc.
Selected listing: ARVN · NASDAQ · USD · US
This page tracks Arvinas, Inc.'s ARVN:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ARVN:NASDAQ. ARVN:NASDAQ is the stock-level entry point for investors researching Arvinas, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Arvinas, Inc. is a public company traded under the ticker ARVN in the American market. The company has a market capitalization of approximately $518 million. Arvinas focuses on developing innovative therapies for various diseases using its proprietary protein degradation technology.
- Ticker
- ARVN:NASDAQ
- Asset type
- Stock
- Market cap
- $600.2M
- Sector
- Health Technology
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
Arvinas, Inc. ARVN:NASDAQ stock context
This page tracks Arvinas, Inc.'s ARVN:NASDAQ listing on NASDAQ in USD for US, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following ARVN:NASDAQ. ARVN:NASDAQ is the stock-level entry point for investors researching Arvinas, Inc., while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary. Arvinas, Inc. is a public company traded under the ticker ARVN in the American market. The company has a market capitalization of approximately $518 million. Arvinas focuses on developing innovative therapies for various diseases using its proprietary protein degradation technology.
Latest news from Arvinas, Inc.
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 4, 2026
Arvinas to Report Second Quarter 2026 Financial Results on August 4, 2026
July 28, 2026
Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease
June 4, 2026
Arvinas Employees Give Back During Company-wide Impact Day
May 18, 2026
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 12, 2026
Arvinas, Inc. earnings calls
Arvinas, Inc. (ARVN) Q2 2026 Earnings Call
August 4, 2026 · Replay with transcript and chapters
Arvinas, Inc. (ARVN) Q1 2026 Earnings Call
May 12, 2026 · Replay with transcript and chapters
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call
February 24, 2026 · Replay with transcript and chapters
Arvinas, Inc. (ARVN) Q3 2025 Earnings Call
November 5, 2025 · Replay with transcript and chapters
Arvinas, Inc. (ARVN) Q2 2025 Earnings Call
August 6, 2025 · Replay with transcript and chapters
Arvinas, Inc. (ARVN) Q1 2025 Earnings Call
May 1, 2025 · Replay with transcript and chapters
Research Arvinas, Inc.
Arvinas, Inc. investor report
Review AI stock analysis and investor report context for ARVN:NASDAQ.
Arvinas, Inc. company profile
View the public company page for Arvinas, Inc. on 6ix.
Arvinas, Inc. news
Read company news and market updates connected to Arvinas, Inc..
Arvinas, Inc. investor events
Find investor webinars, events, and replay context for Arvinas, Inc..